Menu
← Oncology Approval Tracker
FDA DECISION ·
Pemetrexed Injection (Actavis) + pembrolizumab and platinum
pemetrexed plus pembrolizumab and platinum chemotherapy · Actavis
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Initial treatment with pembrolizumab and platinum chemotherapy in metastatic nonsquamous NSCLC without EGFR or ALK genomic aberrations, using the specified pemetrexed product.
LAMPGEN ANALYSIS
Why it matters
The decision adds the immunochemotherapy combination to this product’s labeled use.
What research teams should watch
Verify genomic testing and product-level labeling when reconciling the regimen in pharmacy.
PRIMARY RECORDS